换一批Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
第一作者：
Daniel,Keizman
第一单位：
Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Israel. danielkeizman@gmail.com
作者：
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);骨肿瘤(Bone Neoplasms);癌, 肾细胞(Carcinoma, Renal Cell);二膦酸盐类(Diphosphonates);用药计划表(Drug Administration Schedule);女(雌)性(Female);人类(Humans);吲哚类(Indoles);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);中年人(Middle Aged);吡咯类(Pyrroles);回顾性研究(Retrospective Studies);治疗结果(Treatment Outcome)
DOI
10.1016/j.ejca.2012.02.050
PMID
22409947
发布时间
2019-12-10
- 浏览147
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
